Abstract:Myocardial infarction (MI) is a severe clinical condition caused by myocardial degeneration or necrosis and has high mortality and morbidity rates despite substantial improvements diagnosis and treatment over the past decade. [ 1 ] Due to the immediate reperfusion strategy and other medical therapies, the effectiveness of treatment of MI has been greatly improved. Nevertheless, challenges remain. Patients who develop cardiogenic shock still have a high 30-day mortality of at least 40%. [ 2 ] Rapid diagnosis can significantly reduce the mortality of MI. Currently, MI is usually diagnosed by observing changes via an electrocardiogram or assessing myocardial injury biomarkers, such as cardiac troponin I/T or the MB isoenzyme of creatine kinase. However, these diagnostic methods lack sufficient specificity and sensitivity, leading to misdiagnosis. [ 3 ] Therefore, exploring novel diagnostic and prognostic biomarkers with high sensitivity and specificity, could pave the way for the ongoing discovery of new therapeutic targets for MI. [ 4 ]

Construction of LncRNA-mediated CeRNA network for investigating the immune pathogenesis of myocardial infarction